Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular Death.

The article discusses empagliflozin and cardiovascular death. Topics discussed include the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA), and empagliflozin as an inhibitor of the sodium-glucose cotransporter two which has been approved for the treatment of type 2 diabetes mellitus.